Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — H1 FY2025 Earnings Presentation
21 slides from Atomo Diagnostics's earnings presentation, Feb 28, 2025
Slide 1: H1 FY2025 Results Presentation
H1 FY2025 RESULTS PRESENTATION ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on information The information presented in this presentation is subject to change without notice and Atomo does available as at the date of this presentation. The information in this presentation is provided
Slide 3: Who is Atomo and what do we do?
WHO IS ATOMO AND WHAT DO WE DO? WHO IS ATOMO? WHAT DO WE DO? • Headquartered in Australia, with a low-cost certified facility in Atomo develops solutions that transform the user experience and minimize errors South Africa, we develop, manufacture and supply innovative common in rapid blood test envi
Slide 4: Solutions that deliver
SOLUTIONS THAT DELIVER Initial solutions focused on transforming usability in the lateral flow market Issues with Standard Multi-Component Test Kits Advantages of Atomo Devices “Simple to use! Brilliant! I would rather pay for this test in future if it “The lancet would not be out of place in a Chri
Slide 5: Investment Highlights
INVESTMENT HIGHLIGHTS • Opportunity to invest in a disruptive innovator with unique user focused solutions • Potential to disintermediate lateral flow point of care diagnostics. • Strong FY24 revenue growth (>80% pcp) • Access to multiple large, growing global diagnostic markets in Infectious Diseas
Slide 6: Atomo H1 FY2025 Financial Results
ATOMO H1 FY2025 FINANCIAL RESULTS
Slide 7: H1 FY25 – Profit & Loss
H1 FY25 – PROFIT & LOSS • Total customer revenue increased 7% in comparative periods, AUD H1 H1 (%) with gross margin maintained at 45% FY25($m) FY24($m) • Revenue of $2.05m includes $1.33m relating to POC test sales and Revenue 2.05 1.92 7% $465k relating to sales of POC technology and remaining $2
Slide 8: H1 FY25 – Balance Sheet
H1 FY25 – BALANCE SHEET H1 FY25 FY24 • Cash balance of $2.9m at 31 December 24 and debt free AUD ($m) ($m) • Capitalised expenditure relating to R&D and PPE was insignificant Cash and cash equivalents 2.90 3.69 during the period. With investment in infrastructure completed Trade and other receivable
Slide 9: H1 FY25 – Cash Flow
H1 FY25 – CASH FLOW H1 FY25 Cashflow activities ($'m) 8.00 • Cash receipts of ~$2.6m from customers 7.00 • An additional $761k received from the R&D tax rebate and $485k first 6.00 milestone payment received for CRC-P Active Syphilis grant awarded 5.00 • Cash payments for stock of ~$1.1m • Opex, cap
Slide 10: Fundamentals & Trends
FUNDAMENTALS & TRENDS Core Revenue (FY22 to date) Operating Expenditure (FY22 to date) 2.5 6 5 2 4 1.5 A$ (M) A$ (m) 3 1 2 0.5 1 0 0 H1 FY22 H2 FY22 H1 FY23 H2 FY23 H1 FY24 H2 FY24 H1 FY25 H1 FY22 H2 FY22 H1 FY23 H2 FY23 H1 FY24 H2 FY24 H1 FY25 HIV OEM Development fees/other • Both Revenue (excld CO
Slide 11: Atomo Products
ATOMO PRODUCTS • FINISHED LFA TESTS • TEST DEVICES • DEVELOPMENT PIPELINE
Slide 12: Atomo Product Platform & Pipeline | Summary
ATOMO PRODUCT PLATFORM & PIPELINE | SUMMARY • The only HIV self-test approved in Australia, also approved for sale in the UK and supplied through Boots and Tesco’s and in Europe. Registered in more than twenty countries in HIV Self-Test developing markets. Prequalified by the WHO, making it a global
Slide 13: Current Product Registrations
CURRENT PRODUCT REGISTRATIONS Product Registrations – Atomo as Listed Manufacturer HIV Self Test | US$4bn (2026) [Source] • TGA | Australia • WHO PQ | LMICs • CE Mark | UK & Europe COVID-19 Antibody Test (Discontinued) • TGA | Australia Product Registrations – Atomo Partners Pregnancy Test | US$2.1b
Slide 14: Atomo HIV Self Test
ATOMO HIV SELF TEST ATOMO IS SEEING TWO KEY DRIVERS OF LONG-TERM GROWTH: o Expansion of Markets in Pharmacy/Retail post COVID o Emergence of Public Health Procurement for Self-Testing • HIV revenues more than double from $1.56m in FY23 to US$3.3m in FY24 • Australian Federal Government adopts HIV Se
Slide 15: Atomo HIV Self Test – Future Outlook
ATOMO HIV SELF TEST FUTURE OUTLOOK o HIV self-testing is expected to grow to US$531m by 2026 at a CAGR of 30% [Source]. High growth rate driven by convenience and privacy offered by self-testing, as well as growing adoption of self-test policy and procurement of self-tests by public health bodies o
Slide 16: Pascal Cassette
45° IQ2 PASCAL CASSETTE 360° Pascal delivers unmatched performance and best in-class usability in point-of-care and self-test settings. Platform fully developed and commercialised for OEM Built-In Safety Lancet 70° • Eliminates the risk of hazardous sharps injuries by locking the needle inside the d
Slide 17: Current OEM Customers
CURRENT OEM CUSTOMERS PASCAL IS THE IDEAL SOLUTION FOR PARTNERS DEVELOPING RAPID BLOOD TESTS REQUIRING USABILITY AND RELIBILITY IN DEVELOPMENT Lumos Diagnostics is a US company specialising in rapid, cost- NG Biotech is a French diagnostics company focusing on the Atomo has supplied the Burnet Insti
Slide 18: Atomo Syphilis Test
ATOMO SYPHILIS TEST In Development ATOMO IS SEEKING TO BE FIRST TO MARKET WITH A RAPID TEST THAT CAN DISTINGUISH BETWEEN ACTIVE AND PRIOR TREATED SYPHILIS INFECTION: • Syphilis, has re-emerged as a significant global public health threat . Syphilis testing market is expected to be worth around US$1.
Slide 19: Florey Cassette (Blood)
IN DEVELOPMENT FLOREY CASSETTE (BLOOD) x DESIGNED TO MINIMIZE ADOPTION BARRIERS WITH EXISTING STANDARD TESTS APPROVED AND IN-MARKET • Regulatory Burden - Florey is a usability accessory with lower barriers to introduction as the approved test assay /cassette IVD does not change • Operations impact –
Slide 20: Curie Cassette (Swab)
IN DEVELOPMENT CURIE CASSETTE (SWAB) INTERNAL CHAMBER CAN BE RESIZED & OPTOMIZED FOR NASAL, ORAL AND VAGINAL SWABS 360° Compatible With Existing Swab-Based LF Strip Tests, Curie simplifies workflow complexity, improves inter-operator variability and strengthens assay signal intensity IQ2 Improved Sa
Slide 21: Business Priorities for 2025
BUSINESS PRIORITIES FOR 2025 1. EXPAND HIV SALES REVENUE: 2. PROGRESS ACTIVE SYPHILIS PRODUCT: 3. GROW US CUSTOMER BASE • Continue support for existing HIV • Sign Commercialisation Agreement • Continue support for existing distributors internationally with Burnet early February – Pascal customers •